India, Oct. 12 -- On Sunday, Freenome, Inc. (FRNM) said it will present new clinical validation data for an updated version of its SimpleScreen colorectal cancer (CRC) blood-based screening test at the American College of Gastroenterology (ACG) 2026 Annual Meeting in Nashville.
SimpleScreen CRC is a blood-based screening test designed to detect colorectal cancer and precancerous lesions. The first-generation version received FDA approval in July 2026 and was commercially launched in the U.S. in late September through Freenome's partner Abbott Cancer Diagnostics.
The updated test demonstrated 18.2% sensitivity for advanced precancerous lesions (APLs), compared with 13.7% in the original PREEMPT CRC study.
Sensitivity for APLs with high-gr...